Volume : 09, Issue : 06, June – 2022



Authors :

Dr. S. Shruthi, Dr. T. Rajitha Sree, Dr.Chandrasekhara Rao. B

Abstract :

NAFLD (Non-Alcoholic Fatty Liver Disease) is the accumulation of excess fat in the liver. It is associated with metabolic disorders such as hyperlipidaemia, obesity, hypertension, and Diabetes Mellitus. Kisspeptin (KP) is a naturally occurring hormone in the human body produced from the kisspeptin neurons of the hypothalamus. It is encoded by a gene KISS1 and acts on the KISS 1R receptor. The name originates from the iconic chocolate “HERSHEY’S KISSESS, Pennsylvania”. It has shown promising results in the treatment of NAFLD and progression to NASH (Non-Alcoholic Steatohepatitis), Cirrhosis and HCC (Hepato Cellular Carcinoma). High fat diet (HFD) fed mice/western diet i.e., NAFLD induced mice are treated with Kisspeptin which showed no fatty liver. When KISS1R receptor is deleted from the liver cells of NAFLD induced mice it developed fatty liver even though they are treated with KP’s. In patients diagnosed with NAFLD and NASH there is increased level of Kisspeptin as a part of body’s physiological mechanism. Additionally, it has many advantages on different organs. No side effects were seen with Kisspeptins in all the indications.
Keywords: Kisspeptins, NAFLD, Steatosis, Cirrhosis, Carcinoma, NASH, Hershey’s Kissess.

Cite This Article:

Please cite this article in press Manoj Kumar et al, Kisspeptin – Naturally Occurring Hormone For NAFLD.,Indo Am. J. P. Sci, 2022; 09(6).,

Number of Downloads : 10


1. https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/
2. https://www.icd10data.com/ICD10CM/Codes/K00-K95/K70-K77/K76-
3. https://www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver- disease/symptoms-causes/syc-20354567
4. Christopher Sivell. Nonalcoholic Fatty Liver Disease: A Silent Epidemic. Gastroenterology nursing : the official journal of society of gastroenterology Nurses and Associates. 2019 September/October; 42(5):428-434.
5. Tommy Pacana, Arun J. Sanyal. Vitamin E and Non-alcoholic Fatty Liver Disease. Current Opinion in Clinical Nutrition and Metabolic care. 2012 November; 15(6): 641– 648.
6. Michelle L. Gottsch, Donald K Clifton. From KISS1 to Kisspeptins: An Historical Perspective and Suggested Nomenclature. Peptides. 2009 January; 30(1): 4-9.
7. https://www.rutgers.edu/news/kisspeptin-new-drug-treat-liver-disease#main-content
8. https://www.imperial.ac.uk/news/235280/kisspeptin-reduces-liver-damage-non- alcoholic-fatty/
9. J. Vikman, B. Ahrén. Inhibitory effect of kisspeptins on insulin secretion from isolated mouse islets. Diabetes, Obesity and Metabolism A Journal of Pharmacology and Therapeutics. 2009 November; 11(s4):197-201.
10. Andreas Stengel, Lixin Wang. Centrally injected kisspeptin reduces food intake by increasing meal intervals in mice. Neuroreport. 2011 March 30; 22(5): 253-257.
11. Tien S. Dong, John P. Vu et al. Intraperitoneal Treatment of Kisspeptin Suppresses Appetite and Energy Expenditure and Alters Gastrointestinal Hormones in Mice. Digestive Diseases and Sciences. 2020 August; 65
12. Karolina Skorupskaite, Jyothis T George et al. The kisspeptin-GnRH pathway in human reproductive health and disease. Human Reproductive Update. 2014 March 09; 20(4): 485–500.
13. Channa N Jayasena, Ali Abbara et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54. The Journal of Clinical endocrinology and metabolism. 2014 June; 99(6): E953-61.
14. https://peptidesworld.com/product/kisspeptin/
15. https://pubchem.ncbi.nlm.nih.gov/compound/Kisspeptin-10_-human